GENITOURINARY CANCERS

A supplemental biologics license application has been submitted to the FDA for nogapendekin alfa plus Bacillus Calmette-Guérin in papillary non-muscle invasive bladder cancer.

During a live event, Matthew Galsky, MD discussed neoadjuvant and adjuvant options for a patient case including nivolumab or dose-dense MVAC.

The FDA has approved bevacizumab-nwgd, a biosimilar to bevacizumab, for intravenous use across multiple cancer types.

Cedric Pobel, MD, discusses how the results of the PEACE-1 trial support the use of radiotherapy plus standard of care and abiraterone in low-volume metastatic castration-sensitive prostate cancer.

Hedyeh Ebrahimi, MD, MPH, discusses updated data from a phase 1 study of CBM588, cabozantinib, and nivolumab in metastatic renal cell carcinoma.

Matt Galsky, MD, discusses the phase 3 NIAGARA trial that led to the recent FDA approval of durvalumab in muscle-invasive bladder cancer after radical cystectomy.

Matt Galsky, MD, delved into the recent approval of a perioperative durvalumab regimen in muscle-invasive bladder cancer.

The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic castration-resistant prostate cancer.

Neal Shore, MD, FACS, discussed findings from the SunRISe-4 trial of TAR-200 and cetrelimab in muscle-invasive bladder cancer.

Paul B. Renz, DO, discusses anecdotal changes observed by clinician researchers using the MR-LINAC system.

Investigators found that higher persistent PSA levels after surgery were linked to a worse prognosis, underscoring the importance of timing in post-operative care.

During a live event, Sumanta K. Pal, MD, discusses the efficacy and safety findings from the CheckMate 274 trial of adjuvant nivolumab in patients with bladder cancer.

The first patient has been enrolled in the PROSTATE-IQ trial of ArteraAI, a multimodal artificial intelligence biomarker test.

177Lu rhPSMA-10.1 showed high tumor radiation with low healthy tissue exposure in a phase 1/2 trial for metastatic castration-resistant prostate cancer.

BCG with gemcitabine was linked to strong early oncological efficacy and safety in previously treated patients with non–muscle-invasive bladder cancer.

In an interview, Regina Barragan-Carrillo, MD, highlighted the ongoing global disparities in renal cell carcinoma clinical trials.

Amarnath Challapalli, MBBS, MD, MRCP, FRCR, PhD, discusses some of the most promising findings from the EPIC-A trial of cemiplimab with chemotherapy in treating locally advanced or metastatic penile carcinoma.

The FDA granted priority review to TLX250-CDx for clear cell renal cell carcinoma imaging, with a PDUFA date of August 27, 2025.

During a live event, participating oncologists discuss the role of ctDNA and molecular testing in muscle-invasive bladder cancer.

Studies from Munich University highlighted quality of life in bladder and prostate cancer at ASCO 2025 Genitourinary Cancers Symposium.

Over 90% adherence to relugolix in patients with Medicare with prostate cancer for 24 months supports its use as androgen deprivation therapy, per real-world study data.

OPTYX study shows many patients with advanced prostate cancer preferred oral relugolix over injectables for androgen deprivation therapy.

Cemiplimab plus chemotherapy showed efficacy and consistent safety in advanced penile cancer in the phase 2 EPIC trial.

A review of 50 studies confirmed the safety and efficacy of radium-223 for metastatic castration-resistant prostate cancer treatment.

High prostate-specific antigen levels before High-Intensity Focused Ultrasound were linked to higher recurrence and treatment failure in intermediate-risk prostate cancer.